This record was last updated July 31, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
Bell's palsy, a peripheral facial nerve paresis, is the most common disorder of the facial nerve and one of the most common mononeuropathies.
Many patients with Bell's palsy will develop some complications such as synkinesis, crocodile tears and 'sweating' of the ear while eating Commonly used medications to treat Bell's palsy is Corticosteroids Cerebrolysin stimulates the regeneration of the nervous tissue with protective action we aim to study the efficacy of cerebrolycin in Bell's palsy
Protocol Amendment History
4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-04-07; most recent amendment 2025-07-28.
Status change: Enrolling by Invitation → Recruiting2023-05-03